Quarterly report
Open the filing on sec.gov
Halozyme Therapeutics, Inc. (HALO)
Nasdaq: HALO · Biological Products, (No Diagnostic Substances) · San Diego, CA · filing with the SEC since 2001
Grade6.8
◀ Past 7.9● Present 7.3▶ Future 5.2
The companyfiscal 2025, as filed
Revenue$1.40B+37.6%
Net income$317M-28.6%
Earnings per share$2.56-25.4%
Operating cash flow$652M+36.0%
Cash$134M+15.5%
Debt$2.14B+42.3%
Shareholders’ equity$48.8M-86.6%
Shares, diluted123.9M-4.3%
Return on equity649.2%
The recordfrom its filings
Filings in 202686
Newest filingNov 5 · 10-Q
Annual reportFeb 17, 2026
Quarterly reportNov 5, 2026
Next report due10-K by Mar 1
Insider sales, 12 months$48.4M
Insider buys, 12 months$0.00
Patents granted202
Filer categoryLarge accelerated filer
Trailing twelve months to Sep 2026Revenue $1.80BNet income $485MCash from operations $898Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
As filed, in USD. Nothing here is a forecast.
News
Results released
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report, amended
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider holding, initial
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Nothing of this kind is on the record for this company yet.
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.